- Raised $24.8M PIPE, Jun 2025
- Raised $1.5M funding round, Sep 2020
- Raised $1M funding round, May 2020
About
Matricelf is a preclinical-stage biotechnology company redefining personalized regenerative medicine through its groundbreaking platform for autologous 3D tissue engineering. Founded in 2019, the company develops curative, patient-specific therapies aimed at restoring function and independence in patients with severe neurological injuries, with a lead program targeting spinal cord injury (SCI). Matricelf engineers functional 3D neural implants using induced pluripotent stem cells (iPSCs) and extracellular matrix derived from each patient's own tissue. The company is preparing for a First-in-Human clinical trial planned for 2027, in collaboration with Sheba Medical Center, and is also exploring additional indications in cardiovascular and retinal diseases, stroke, and traumatic brain injury.
Funding history · 3 rounds · $34.8M total
Q&A
- What is Matricelf's primary focus?
- Matricelf is a preclinical-stage biotechnology company focused on personalized regenerative medicine, developing autologous 3D tissue engineering for severe neurological injuries, with a lead program targeting spinal cord injury (SCI).
- When was Matricelf founded and where is its headquarters located?
- Matricelf was founded in April 2019 and is headquartered in Ness Ziona, Israel.
- What is Matricelf's employee count?
- Matricelf has an employee count in the 11-50 range.
- What is the total amount of funding Matricelf has raised to date?
- Matricelf has raised a total of $34,843,000 USD.
- When was Matricelf's most recent funding round and how much was raised?
- Matricelf's most recent funding round was a PIPE in June 2025, raising $24,800,000 USD from qualified and strategic investors.
- Who are the co-founders of Matricelf?
- Matricelf was co-founded by Alon Sinai and Prof. Tal Dvir.
- What is Matricelf's lead product program?
- Matricelf's lead product program is focused on developing curative, patient-specific therapies for spinal cord injury (SCI).
- What are Matricelf's future clinical trial plans?
- Matricelf is preparing for a First-in-Human clinical trial planned for 2027, in collaboration with Sheba Medical Center.
Team · 19
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | matricelf.com/ |
|---|---|
| linkedin.com/company/34957760 |
Identifiers & details
| Legal name | Matricelf Ltd. |
|---|---|
| Founded | 2019-4 |
| Employees (exact) | 16 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Web history (Wayback)
| Domain | matricelf.com |
|---|
Certificate / subdomain footprint
| Subdomains | 7 |
|---|